Exploring the Potential Drug Target and Biomarker TCTN1 (FLJ21127)

Target Name: TCTN1

NCBI ID: G79600

TCTN1

Exploring the Potential Drug Target and Biomarker TCTN1 (FLJ21127)

Introduction

Tumor-associated extracellular matrix (TCE) proteins, such as TCTN1 (FLJ21127), play a crucial role in cancer progression and the development of various diseases. These proteins help to maintain the structure and integrity of cancer cells, allowing them to evade the host immune system and continue to grow and multiply. TCE proteins have also been identified as potential drug targets and biomarkers, offering a promising avenue for cancer treatment. In this article, we will explore the potential drug target and biomarker TCTN1 and its implications in cancer research and treatment.

Potential Drug Target: TCTN1 and Cancer Treatment

TCTN1 is a non-coding RNA molecule that is expressed in various tissues of the body, including the immune system, skin, and nervous system. It is a member of the tight gene family, which includes several well-known proteins, including tight junction protein (TJP) 1,2, and 3. TCTN1 is primarily composed of introns and exons, with the exception of a non-coding region that is sometimes referred to as the \"Promotor.\"

Recent studies have suggested that TCTN1 may have potential as a drug target for cancer. For instance, TCTN1 has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. It has also been shown to promote the growth and survival of cancer cells in various signaling pathways, including the TGF-β pathway.

One of the key advantages of targeting TCTN1 is its potential to be a once-daily drug, as TCTN1 is expressed in most tissues of the body and can be easily measured in blood samples. Additionally, TCTN1 is a protein that is expressed in high levels in cancer cells, making it an attractive target for small molecules that can inhibit its activity.

Biomarker Potential: TCTN1 as a Cancer Biomarker

In addition to its potential as a drug target, TCTN1 has also been identified as a potential biomarker for cancer. The ability of TCTN1 to be expressed in various tissues and to be affected by cancer treatments suggests that it may serve as a valuable diagnostic or predictive marker for cancer.

One of the key advantages of using TCTN1 as a biomarker is its stability and persistent expression in various tissues. This stability allows for TCTN1 to be used as a biomarker for cancer that has progressed to a later stage, as it is less likely to be affected by early-stage treatments. Additionally, the consistent expression of TCTN1 in various tissues makes it a valuable marker for cancer that has been treated with various drugs, allowing researchers to determine the effectiveness of these treatments.

Conclusion

TCTN1 is a non-coding RNA molecule that has been shown to play a role in the development and progression of various cancers. Its potential as a drug target and biomarker make it an attractive candidate for cancer research and treatment. Further studies are needed to determine the full implications of TCTN1 in cancer research and treatment.

Protein Name: Tectonic Family Member 1

Functions: Component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes. Regulator of Hedgehog (Hh), required for both activation and inhibition of the Hh pathway in the patterning of the neural tube. During neural tube development, it is required for formation of the most ventral cell types and for full Hh pathway activation. Functions in Hh signal transduction to fully activate the pathway in the presence of high Hh levels and to repress the pathway in the absence of Hh signals. Modulates Hh signal transduction downstream of SMO and RAB23 (By similarity)

The "TCTN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCTN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets